Helicobacter pylori vaccine - Emergent BioDefense Operations Lansing

Drug Profile

Helicobacter pylori vaccine - Emergent BioDefense Operations Lansing

Alternative Names: Helivax

Latest Information Update: 09 Feb 2007

Price : $50

At a glance

  • Originator Emergent BioDefense Operations Lansing
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Helicobacter infections

Most Recent Events

  • 09 Feb 2007 Discontinued - Phase-I for Helicobacter infections in USA (PO)
  • 16 Jun 2003 The assets of Antex Biologics and Antex Pharma have been acquired by BioPort Corporation
  • 31 Jan 2003 Antex Biologics has received approval from the FDA for its IND application for its Helicobacter pylori vaccine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top